BAVARIAN NORDIC - 1000% pumpI expect a very strong increase in this company’s stock due to the impending monkeypox problem. Therefore, it is a very good idea to buy it. Wishing everyone health and prosperity.
NORDIC
Pharma firm SIGA cashes in on monkeypox scareNew York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox.
Smallpox jabs vs monkeypox
On May 19, the World Health Organization declared that vaccines used against smallpox — before the virus was eradicated in 1980 — can be used to fight monkeypox. SIGA already won approval from the US Food and Drug Administration in 2018 to distribute its oral TPOXX capsules as a treatment against smallpox even when there were no reports of confirmed or possible cases of smallpox at the time.
US advances in vaccine orders
Most recently, SIGA on Thursday secured another approval from the FDA for the intravenous (IV) formulation of TPOXX for patients who are unable to swallow the drug’s oral variant. SIGA said the IV formulation of TPOXX has already been cited in the recent US president’s budget request to treat a patient with monkeypox in the US.
The company's shares surged 43% on Friday before paring gains to close 13% lower on the Nasdaq on Monday, and another 15.5% on Tuesday. SIGA stock remains up 26.5% over the past 5 days of trading.
SIGA also stands to benefit from TPOXX’s use in Canada and Europe, where cases of moneypox were detected in recent weeks. Europe has already approved the use of TPOXX against monkeypox, cowpox, and complications from immunization with vaccinia, the company said.
Growing monkeypox threat
Monkeypox, first discovered in 1958, is a viral illness that first occurred in colonies of monkeys. The first human case of the virus was recorded in the Democratic Republic of Congo in 1970, according to the US Centers for Disease Control and Prevention. The virus can cause symptoms like fever, body aches, swollen lymph nodes and bumpy rashes.
Cases of monkeypox have so far been reported in at least 17 countries including the US, Canada, the UK, Spain, Portugal, France, Italy and Australia.
Big pharma steps in
SIGA and another vaccine maker in Denmark, Bavarian Nordic (CPH:BAVA), have kept samples of smallpox virus for research purposes in case of biological warfare. The emergence of monkeypox this year prompted both companies to start mass producing vaccines against smallpox to offer protection against monkeypox.
CDC officials on Monday said the US is in the process of releasing Bavarian Nordic’s Jynneos vaccine doses to fight against monkeypox. The US has stockpiled more than 1,000 doses of the vaccine and CDC officials expect to boost their purchases in the coming weeks.
Bavarian Nordic’s shares on the Nasdaq Copenhagen surged to a four-month high on Monday.
The Danish company on May 18 said the US government has already placed a $119 million order for the production of freeze-dried Jynneos vaccines, although deliveries are not expected until 2023 and 2024.
Meanwhile, Moderna (NASDAQ:MRNA), which succeeded in developing vaccines against COVID-19, also started testing vaccines against monkeypox. The company on Tuesday said it is investigating potential vaccines against monkeypox in pre-clinical trials.
No urgent need for mass vaccinations
Although vaccines against monkeypox are already within reach just weeks into reports of an outbreak emerged, some experts and WHO officials say inoculations against monkeypox will not likely involve a mass campaign as the virus, unlike COVID-19, is not as contagious. Vaccinations would likely be focused only on people with close contact with infected individuals.
"If a case is reported in the country, a public health SWAT team goes out, finds out who the close contacts are of that first case, and vaccinates just those close contacts, and not the entire city or suburb,” Dr. David Freedman, professor emeritus of infectious diseases at the University of Alabama, was quoted by Time magazine as saying.
Investor. The King of Sweden. Stable and fast. But not for long.Investor. The King of Sweden. Stable and fast. But not for long.
Like all stocks. we are going down. Momentum and bubble is about to burst.
CDON Retracement Near Completion Buy Opportunity
CDON listed back in Nov 2020 and from 96 SEK up to its ATH of 975 SEK in January 21
its bullish cycle came to a stop at the start of FEB 21 .
CDON has nearly completed its retracement/correction from its dizzy highs of 975 SEK down to
current levels of 430SEK but expecting 300SEK.
and will be presenting a speculative Buy Opportunity .
Price action is trading within this falling wedge, I have done a standard FIB Retracement Pull from the Hi to Lo
and Volume has clearly depleted during this continued move to the downside as presented .
I would like to see the PA go down to the .786 fib level but of course it does not have too .
We can also build support at the current level 0.618, in which case if you wanted to buy then you should wait for a candle
close outside of the resistance . Until then though i expect sideways then one leg down eventually .
Please be aware that this is a highly speculative opportunity for the reasons i have provided below .
DYOR and know your invalidation and always use a SL .
Like and Follow for continued Analysis
21st April
CDON Q1 EBITDA Loss Widens To SEK 9.0 Million
5th March
CDON's CEO Kristoffer Väliharju Temporarily Resigns As CEO
10th May
CDON CEO Kristoffer Väliharju Resigns
8 June (Reuters) - CDON AB CDONAB.ST :
* SUSTAINABILITY IN FOCUS AS CDON AND BRING SIGN A LOGISTICS AGREEMENT
* CDON AND BRING HAVE SIGNED A NEW LOGISTICS AGREEMENT FOR SCANDINAVIAN COUNTRIES,
WHICH ENTAILS AN INCREASED FOCUS ON SUSTAINABLE DELIVERIES.
A nordic crypto exchange Dipping below the previous resistance (which is a dangerzone/sign). New investors got cold feet from Mr. Musk rant and BTC drop. With slow crypto recovery, this will bounce back to 6-7. That is a quick gain of 30-40% – if offc. you do think crypto will not go away. As the CEO stated -they actually earn money both when the market go up and when it goes down. Long or short timeframe –> Bullish
CN1 Bull PositionThe weekly candle has bounced nicely from the top of the Keltner channel continuing its bull run. We'll see where it goes from here. I personally have a buy position on this instrument.
Sivers 5G mmwave - four F100 and more on the way - multibagger?Sivers has leading tech in their space: microwave, millimeter wave and laser products which enable reliable Gigabit speeds for 5G and beyond.
Hypothesis: I believe the company will high single digit x the value of today.
Data points and information from the company:
It looks like quite a lot of institutional buys the last days. One huge swedish investor took a big stake the recent weeks.
Sivers IMA Holding also intends to change the names of its subsidiaries to Sivers Wireless (formerly Sivers IMA AB) and Sivers Photonics (formerly CST Global) to better reflect their respective markets.
"The name change is part of a larger marketing and branding work that we have been working on for a long time to clarify the common identity within the Group and to further clarify and strengthen our profile towards investors and customers on a global level. We intend to launch the new brands before the end of the year, well in advance of a possible listing on Nasdaq Stockholm's main list in the first half of 2021."
Sivers IMA which is a small cap company of USD 550 million have been winning 19 design wins which are now materialising into larger contracts. The last order was SEK 400 million which is around USD 50 million.
You can watch the interim report here (in english):
www.siversima.com
Links about mmwave tech and breakthrough
venturebeat.com
Will update
I will update with more info when I've bought more shares in a few days. Hint: Fortune 100 contracts.
Bayn GroupFundamentals for this M&A food tech company which focuses on acquiring consumer facing brands like Pändy and Tweek looks quite promising. Bayn Group has cutting edge and healthy sugar reduction solutions which can be used in the food and beverage industry.
They have 100+ million in cash for acquisitions.
They have a clear strategy, economic muscles and have had great execution these last months. They have new leadership and they have managed to recruit active and competent owners and a great advisor team.
I think we're going up above 10 where ascending trend line meets resistance, could move up before also. Volume trend indicates more strength for the long side.
Nordic american tankers Ready to pop upit turned out to notice the trend channel, which leads to the closing of the gap. There is a possibility that the company will return the trust of investors. But it will be very gradual.. I wish the company success!
NANO strong momentum after reversal at bottom of long downtrendNorwegian smallcap biotech Nordic Nanovector recently had a major capitulation event after touch the bottom of yearlong downtrend fueled by weak biotech sentiment on Oslo stock exchange as well as a pronounced distrust to CEO in the norwegian investor community.
After former CEO Lugi Costa resigned sentiment has changed drastically, and the stock looks poised to make a leap back to the old NOK 68-94 trading range. Close above NOK 64 the nearest days would be a strong buy signal.
Nano down before up againGot to mention I'm new to Tech Analyzing. Please comment. Negative and positive feedback is appreciated.
I think Nordic Nano is on a retracting downtrend until the support line around 56. Also period with no news, loosing short-term investors. Head shoulder pattern leads the shortterm downtrend. Grey rectangle is refill area(from the fibbonacci). I'm long this stock. Fundamentals is still really good, so it will come up again following the red uptrend channels. Their medisin works, no real competitors as I know of. People from Algeta-success started this company. Forum people talking about goal around 1000 NOK in 2019-2020 when medisin is expected ready for the market.
